NR 508 Week 2 Dabigatran Pharmacokinetics Write-Up Example

Course	NR 508 Advanced Pharmacology
Week	2
Paper type	Pharmacokinetics write-up
Length	About 1,120 words, 3 pages
Format	APA 7 student paper
School	Chamberlain University
Program	MSN
Updated	October 2026

Free sample paper for NR 508 Week 2

Dabigatran in a 76-Year-Old Man With a Creatinine Clearance of 42: A 3% to 7% Fraction, a Prodrug Cleaved by Esterases, a Kidney That Sets the Clock at 18 Hours, and Two Dates for a Thursday Colonoscopy

Student Name

College of Nursing, Chamberlain University

NR 508: Advanced Pharmacology

Instructor Name

Month Day, Year

What this page is doingThe title follows the drug from route to the dates its half-life produces, which is the schedule the write-up builds. Student APA 7 title page.

The Patient and the Question

Mr. D., 76, has nonvalvular atrial fibrillation and takes dabigatran etexilate 150 mg twice daily. His creatinine clearance, calculated this month, is 42 mL/min. He was started on dabigatran eight weeks ago and is now scheduled for an elective colonoscopy with likely polypectomy on Thursday at 0800. The questions are practical: when did his drug reach steady state after he started it, and when must he take his last dose before Thursday? Both answers come from the pharmacokinetics of this particular molecule in this particular man, and this write-up builds them process by process.

Route Before Anything Else

Dabigatran is taken by mouth as capsules containing the prodrug dabigatran etexilate. The route matters first because the fraction that reaches the blood is small. The prescribing information gives the absolute bioavailability of dabigatran after oral dabigatran etexilate as approximately 3% to 7% (Boehringer Ingelheim Pharmaceuticals, 2025). Part of the reason is that dabigatran etexilate is a substrate of the intestinal efflux transporter P-glycoprotein, which pumps some of the absorbed drug back into the gut lumen.

The capsule itself is part of the dose. The label states that oral bioavailability increases by 75% when the pellets are taken without the capsule shell, and that capsules should not be broken, chewed or opened. For Mr. D., who has some difficulty swallowing large tablets, that detail matters more than any other in this section: opening the capsule to sprinkle it on food would raise his exposure substantially.

A Fraction and a Delay

In the fasted state, peak concentration occurs about 1 hour after a dose. A high-fat meal delays the peak by about 2 hours but does not change the fraction absorbed, so dabigatran may be taken with or without food (Boehringer Ingelheim Pharmaceuticals, 2025). Taken with his breakfast, Mr. D.'s morning dose reaches its peak around mid-morning rather than an hour after he swallows it, which has no effect on his total exposure but explains why a blood test drawn soon after his dose may not reflect the peak.

Where It Sits, and Which Compound Is Working

Dabigatran has a volume of distribution of 50 to 70 L and is only about 35% bound to plasma proteins. It does not concentrate heavily in tissues and does not depend on albumin, so a low albumin would not raise his free drug much. The low protein binding has one further consequence: hemodialysis can remove part of the drug, which is not true of more highly bound anticoagulants.

The molecule he swallows is not the one that works. Dabigatran etexilate is converted to dabigatran, the active direct thrombin inhibitor, mainly by esterase-catalyzed hydrolysis, and dabigatran is not a substrate, inhibitor or inducer of the cytochrome P450 enzymes (Boehringer Ingelheim Pharmaceuticals, 2025). That spares him most of the metabolic interactions that complicate warfarin. The interactions that remain run through P-glycoprotein, at the absorption step, rather than through the liver.

The P-glycoprotein step is where Mr. D.'s other medicines matter. His list includes no strong P-glycoprotein inhibitor, but if a cardiologist later added one, such as dronedarone or systemic ketoconazole, more dabigatran etexilate would stay in the blood at the absorption step, and in a man with moderate kidney impairment the two effects would add together. The label addresses these combinations by kidney function, and any new prescription for him should be checked against that section before the first dose, not after a bleeding event.

What this page is doingEach process is attached to this drug and this patient, with the consequence stated rather than the process defined.

The Organ That Sets the Clock

Dabigatran is cleared mainly by the kidneys: renal clearance accounts for 80% of total clearance. In healthy adults the half-life is 12 to 17 hours. As kidney function falls, exposure and half-life rise. The label's pharmacokinetic table gives a half-life of about 13 hours with normal function, 15 hours with mild impairment, 18 hours with moderate impairment (creatinine clearance 30 to 50 mL/min), and 27 hours with severe impairment, with total exposure in moderate impairment about 3.2 times normal (Boehringer Ingelheim Pharmaceuticals, 2025).

Mr. D.'s clearance of 42 mL/min places him in the moderate group. His kidney, not his liver, sets the clock, and it is running at about 18 hours per half-life. His dose of 150 mg twice daily remains the labeled dose for atrial fibrillation with a creatinine clearance above 30 mL/min, but at a clearance of 42 he is closer to the threshold than to normal, and any fall in kidney function, for example from dehydration during bowel preparation, would lengthen the half-life further.

Two Dates From One Half-Life

Date one: steady state after starting. A drug given at a fixed dose reaches steady state after about four to five half-lives. At 18 hours per half-life, that is 72 to 90 hours, roughly three to four days. Mr. D.'s levels, and his bleeding risk, were still rising during his first several days of treatment and were stable by about the fourth day. The label notes that with twice-daily dosing, dabigatran accumulates to about twice the level of a single dose, which is the level he has had since then.

Date two: the last dose before Thursday. The label advises discontinuing dabigatran 1 to 2 days before invasive procedures when creatinine clearance is 50 mL/min or higher, and 3 to 5 days before when it is below 50 mL/min, with longer times for major surgery or neuraxial procedures (Boehringer Ingelheim Pharmaceuticals, 2025). Mr. D. is below 50, so the window is 3 to 5 days. If he takes his last dose on Sunday evening at 2000, 84 hours will have passed by 0800 on Thursday. At 18 hours per half-life, 84 hours is about 4.7 half-lives, leaving roughly 4% of his steady-state level, a reasonable margin for a polypectomy. If his last dose were Monday morning instead, only 72 hours, or four half-lives, would pass, leaving about 6%.

The two dates together give a plan his nurse can write on a calendar: last dose Sunday at 2000, no doses Monday through Wednesday, procedure Thursday at 0800, and restart as directed by the endoscopist once bleeding risk allows. If his creatinine rises during bowel preparation, the half-life lengthens and the Sunday date should be moved earlier rather than kept.

References

Boehringer Ingelheim Pharmaceuticals. (2025). Pradaxa (dabigatran etexilate mesylate) capsule [Prescribing information]. DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9

The Chamberlain NR 508 Week 2 instructions

For Week 2 you follow one drug through the body of one patient. Expect to cover absorption, distribution, metabolism, elimination, the patient factors that change them and the clinical consequences, with APA. Start with the route, since it decides how much drug reaches the blood. Attach each process to this drug and this patient, stating the consequence rather than defining the term. Identify the organ that sets the clock. Calculate the half-life for this patient where the label allows. Turn the half-life into dates, such as steady state and when to stop before a procedure. Note where food or other drugs change the picture.

How this NR 508 Week 2 example is built

The opening introduces Mr. D. with nonvalvular atrial fibrillation on 150 mg twice daily and his clearance of 42 mL/min. The route section explains low oral bioavailability and the capsule warning. The absorption section reports peak concentration about an hour after dosing and a two-hour delay with fatty meals. The distribution section gives a volume of 50 to 70 L and 35% protein binding. The metabolism section explains esterase conversion to dabigatran and the P-glycoprotein step that a future inhibitor could affect. The elimination section explains renal clearance and the moderate group his clearance places him in. The dates section calculates steady state and a last dose on Sunday at 2000 before a Thursday procedure. Each step of the schedule is written so a nurse could put it on a calendar.

NR 508 Week 2 rubric: what full points look like

Pharmacokinetics rubrics in NR 508 typically score accurate description of each process, application to the patient, identification of key factors, correct use of half-life, clinical consequences and APA. Turning the half-life into two dates is where most of the marks sit, and the arithmetic becomes a calendar a nurse can follow. Each process is credited for being tied to dabigatran. Patient application scores through his kidney function. Key factors earn points for the capsule, food and P-glycoprotein. Consequences are credited for the steady state and procedure timing. The Pradaxa prescribing information supports every figure. One reference completes APA. Showing the arithmetic for steady state lets a grader check the dates.

NR 508 Week 2 help from the desk

A half-life reported and never used costs the most, because the value of the figure is the dates it produces. Another loss is defining absorption, distribution, metabolism and elimination in general without attaching them to the drug. Students also ignore organ function, miss that the drug is a prodrug or skip interactions at transporters. Calculations should be shown simply. An active metabolite changes which compound you follow, as here. Food and other drugs belong where they change absorption or clearance. Send your drug and patient, and an NR 508 write-up can turn the half-life into dates. Show the arithmetic, briefly, for each date.

Get a NR 508 Week 2 example written to your instructions

Send the Week 2 instructions, the template if your classroom posts one, and the agent your section assigned, and a custom example is written to them and returned inside 24 to 48 hours, the first one free. If the drug is left to you, the desk picks one whose numbers are published clearly enough to build a schedule on.

More NR 508 papers and MSN samples

NR 508 Week 2 questions, answered

Does the write-up need calculations in it?

Sections differ on this and some post a worksheet, but even where no arithmetic is required the example still carries figures, because the argument is made of them. Multiples of the half-life are usually enough to produce both dates without any formula. Where a calculation is asked for, it belongs beside the number it produces rather than in an appendix nobody reads.

What if the drug has an active metabolite?

Then the metabolite gets its own line and its own half-life, because the schedule belongs to whichever compound is doing the work. This is the single most common place a write-up ends up describing the wrong molecule: the parent is cleared in hours, the metabolite lingers for days, and every date in the document is out by an order of magnitude.

Where do food and other drugs fit here?

They belong inside the process each one touches rather than in a section of their own. Food and an antacid change absorption, so they sit there. An enzyme inducer changes metabolism and belongs in that paragraph with the direction of the effect stated. Naming an interaction without saying which process it moves leaves a marker nothing to credit.

Where can I find a free NR 508 Week 2 sample paper?

This page has the complete Week 2 pharmacokinetics write-up for dabigatran, from route to elimination, with the patient's half-life, the two dates, the calendar and the prescribing information.

Why does the kidney set the clock in the NR 508 Week 2 write-up?

Because renal clearance accounts for 80% of dabigatran's total clearance, so the patient's reduced creatinine clearance lengthens the half-life to about 18 hours.